Circulating Long RNAs in Serum Extracellular Vesicles: Their Characterization and Potential Application as Biomarkers for Diagnosis of Colorectal Cancer

Background: Long noncoding RNA (lncRNA) and mRNAs are long RNAs (≥200 nucleotides) compared with miRNAs. In blood, long RNAs may be protected by serum extracellular vesicles, such as apoptotic bodies (AB), microvesicles (MV), and exosomes (EXO). They are potential biomarkers for identifying cancer. Methods: Sera from 76 preoperative colorectal cancer patients, 76 age- and sex-matched healthy subjects, and 20 colorectal adenoma patients without colorectal cancer were collected. We investigated the distribution of long RNAs into the three vesicles. Seventy-nine cancer-related long RNAs were chosen and detected using qPCR. Results: The quantity of long RNA has varying distribution among three subtypes of extracellular vesicles in serum. Most mRNA and lncRNA genes had higher quantity in EXOs than that in ABs and MVs, whereas MVs contain lowest quantity. We investigated 79 long RNAs chosen from The Cancer Genome Atlas and the LncRNADisease database in the sera of healthy patients, and those with colorectal cancer. In the training and test sets, the AUCs were 0.936 and 0.877, respectively. The AUC of total serum RNA was lower (0.857) than that of exosomal RNA in the same samples (0.936). Conclusion: The present study shows that exosomal mRNAs and lncRNAs in serum could be used as biomarkers to detect colorectal cancer. Impact: Among three types of vesicles in sera, EXOs were the richest reservoir for almost all measured long RNAs. The combination of two mRNAs, KRTAP5-4 and MAGEA3, and one lncRNA, BCAR4, could be potential candidates to detect colorectal cancer. Cancer Epidemiol Biomarkers Prev; 25(7); 1158–66. ©2016 AACR.

[1]  R. Tibshirani,et al.  Improvements on Cross-Validation: The 632+ Bootstrap Method , 1997 .

[2]  H. Bonnefoi,et al.  Telomerase RNA as a detection marker in the serum of breast cancer patients. , 2000, Clinical cancer research : an official journal of the American Association for Cancer Research.

[3]  Y. Lo,et al.  Circulating Nucleic Acids in Plasma and Serum: An Overview , 2001, Annals of the New York Academy of Sciences.

[4]  F. A. Benko,et al.  Circulating RNA as a Tumor Marker , 2001, Annals of the New York Academy of Sciences.

[5]  Y. Lo,et al.  Stability of endogenous and added RNA in blood specimens, serum, and plasma. , 2002, Clinical chemistry.

[6]  T. Godfrey,et al.  Characterization of amplifiable, circulating RNA in plasma and its potential as a tool for cancer diagnostics. , 2004, Clinical chemistry.

[7]  W. Siegert,et al.  Guideline to reference gene selection for quantitative real-time PCR. , 2004, Biochemical and biophysical research communications.

[8]  N. Shimizu,et al.  Identification of two novel clusters of ultrahigh-sulfur keratin-associated protein genes on human chromosome 11. , 2004, Biochemical and biophysical research communications.

[9]  R. Bremnes,et al.  Circulating tumour-derived DNA and RNA markers in blood: a tool for early detection, diagnostics, and follow-up? , 2005, Lung cancer.

[10]  David Elashoff,et al.  Serum circulating human mRNA profiling and its utility for oral cancer detection. , 2006, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[11]  J. Jass Colorectal cancer: a multipathway disease. , 2006, Critical reviews in oncogenesis.

[12]  Daniel B. Martin,et al.  Circulating microRNAs as stable blood-based markers for cancer detection , 2008, Proceedings of the National Academy of Sciences.

[13]  F. Bosman,et al.  WHO Classification of Tumours of the Digestive System , 2010 .

[14]  Massimo Negrini,et al.  Micromarkers: miRNAs in cancer diagnosis and prognosis , 2010, Expert review of molecular diagnostics.

[15]  Michael J Kerin,et al.  Circulating microRNAs as Novel Minimally Invasive Biomarkers for Breast Cancer , 2010, Annals of surgery.

[16]  Klaus Pantel,et al.  Cell-free nucleic acids as biomarkers in cancer patients , 2011, Nature Reviews Cancer.

[17]  Danielle Meijer,et al.  Characterization of BCAR4, a novel oncogene causing endocrine resistance in human breast cancer cells , 2011, Journal of cellular physiology.

[18]  A. Simpson,et al.  MAGE-A3 is highly expressed in a subset of colorectal cancer patients. , 2012, Cancer immunity.

[19]  Tao Jiang,et al.  Circulating microRNAs in cancer: origin, function and application , 2012, Journal of Experimental & Clinical Cancer Research.

[20]  J. Hou,et al.  Long non-coding RNA metastasis associated in lung adenocarcinoma transcript 1 derived miniRNA as a novel plasma-based biomarker for diagnosing prostate cancer. , 2013, European journal of cancer.

[21]  Hongwei Ma,et al.  Plasma HULC as a Promising Novel Biomarker for the Detection of Hepatocellular Carcinoma , 2013, BioMed research international.

[22]  Shireen S. Rajaram,et al.  A review of global cancer burden: Trends, challenges, strategies, and a role for surgeons , 2013, Journal of surgical oncology.

[23]  U. Gezer,et al.  Investigation of circulating lncRNAs in B-cell neoplasms. , 2014, Clinica chimica acta; international journal of clinical chemistry.

[24]  Pavel Vodicka,et al.  HOTAIR long non-coding RNA is a negative prognostic factor not only in primary tumors, but also in the blood of colorectal cancer patients. , 2014, Carcinogenesis.

[25]  T. Ørntoft,et al.  Cellular disposal of miR23b by RAB27-dependent exosome release is linked to acquisition of metastatic properties. , 2014, Cancer research.

[26]  Allan Stensballe,et al.  Diagnostic and prognostic potential of extracellular vesicles in peripheral blood. , 2014, Clinical therapeutics.

[27]  Midie Xu,et al.  Long non-coding RNAs in colorectal cancer: implications for pathogenesis and clinical application , 2014, Modern Pathology.

[28]  J. Schalken,et al.  Noncoding RNAs as Novel Biomarkers in Prostate Cancer , 2014, BioMed research international.

[29]  Abolfazl Barzegari,et al.  MicroRNAs in colorectal cancer: from diagnosis to targeted therapy. , 2014, Asian Pacific journal of cancer prevention : APJCP.

[30]  A. Jemal,et al.  Colorectal cancer statistics, 2014 , 2014, CA: a cancer journal for clinicians.

[31]  Guoxin Zhang,et al.  Identification of the long non-coding RNA H19 in plasma as a novel biomarker for diagnosis of gastric cancer , 2015, Scientific Reports.

[32]  S. Ni,et al.  Circulating CUDR, LSINCT‐5 and PTENP1 long noncoding RNAs in sera distinguish patients with gastric cancer from healthy controls , 2015, International journal of cancer.

[33]  D. Fliser,et al.  Circulating long noncoding RNATapSaki is a predictor of mortality in critically ill patients with acute kidney injury. , 2014, Clinical chemistry.